| Literature DB >> 35046008 |
Carlo Ammendolia1,2, Corey Hofkirchner3, Joshua Plener3, André Bussières4,5, Michael J Schneider6, James J Young3,7, Andrea D Furlan8,9, Kent Stuber3, Aksa Ahmed2, Carol Cancelliere10, Aleisha Adeboyejo3, Joseph Ornelas11.
Abstract
OBJECTIVES: Neurogenic claudication due to lumbar spinal stenosis (LSS) is a growing health problem in older adults. We updated our previous Cochrane review (2013) to determine the effectiveness of non-operative treatment of LSS with neurogenic claudication.Entities:
Keywords: back pain; clinical trials; epidemiology; neurological pain; pain management; spine
Mesh:
Year: 2022 PMID: 35046008 PMCID: PMC8772406 DOI: 10.1136/bmjopen-2021-057724
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Study flow diagram.
Risk of bias assessment for studies on non-operative treatment for lumbar spinal stenosis with neurogenic claudication
| Author | A | B | C | D | E | F | G | H | I | J | K | L | Total |
| Calcitonin | |||||||||||||
| Eskola | ? | ? | + | + | + | ? | + | – | ? | ? | ? | + | 5 |
| Porter and Hibbert | ? | ? | – | ? | ? | + | + | ? | – | ? | + | + | 4 |
| Porter and Miller | ? | ? | + | ? | ? | – | + | + | ? | ? | ? | + | 4 |
| Podichetty | ? | ? | + | + | + | – | + | – | + | ? | ? | + | 6 |
| Tafazal | ? | ? | + | + | + | + | + | + | – | ? | ? | + | 7 |
| Sahin | ? | ? | – | – | + | – | ? | + | + | ? | ? | + | 4 |
| Oral medications | |||||||||||||
| Prostaglandin | |||||||||||||
| Matsudaria | + | + | – | – | + | + | + | ? | + | ? | ? | + | 7* |
| Methylcabalin | |||||||||||||
| Waikakul and Waikakul | – | ? | – | – | + | + | + | ? | + | ? | ? | + | 5 |
| Gabapentin | |||||||||||||
| Yaksi | ? | ? | – | – | – | ? | + | + | ? | ? | ? | + | 3 |
| Pregabalin | |||||||||||||
| Markman | + | + | + | + | + | + | + | + | ? | + | – | + | 10‡ |
| Gabapentin | |||||||||||||
| Park | + | ? | + | + | + | + | + | + | ? | ? | – | + | 8‡ |
| Oxymorphone hydrochloride | |||||||||||||
| Markman | + | + | + | + | + | – | ? | + | ? | + | + | + | 9†§ |
| Oral corticoid | |||||||||||||
| Rodrigues and Natour | + | + | ? | ? | ? | + | + | ? | ? | ? | ? | + | 5 |
| Rehabilitation therapy or multimodal care | |||||||||||||
| Goren | + | + | – | – | + | + | – | + | + | ? | ? | + | 7* |
| Koc | ? | ? | – | – | + | + | + | – | + | ? | ? | + | 5 |
| Pua | + | + | – | – | + | – | + | + | + | ? | – | + | 7* |
| Whitman | + | ? | – | – | + | + | + | + | + | ? | ? | + | 7 |
| Minetama | + | ? | – | – | + | + | + | + | ? | + | + | + | 8‡ |
| Schneider | + | + | – | – | + | – | + | + | + | ? | + | + | 8* |
| Ammendolia | + | + | – | – | + | + | + | + | + | + | + | + | 10* |
| Oğuz | ? | ? | – | – | ? | ? | + | – | ? | ? | ? | + | 2 |
| Homayouni | + | + | – | – | + | + | + | – | – | + | ? | + | 7† |
| Marchand | + | + | – | – | + | ? | + | + | ? | – | + | + | 7† |
| Kim | + | + | + | + | + | + | + | + | ? | + | + | + | 11* |
| Spinal manipulation | |||||||||||||
| Passmore | – | + | – | – | + | + | + | – | + | + | + | + | 8† |
| Acupuncture | |||||||||||||
| Kim | + | + | – | – | – | – | + | + | – | + | + | + | 7† |
| Qin | + | + | + | – | + | + | + | + | + | – | + | + | 10* |
| Epidural injections | |||||||||||||
| Cuckler | ? | ? | + | + | + | + | + | + | + | ? | + | + | 9 |
| Fukusaki | ? | ? | ? | ? | + | + | + | + | + | ? | + | + | 7 |
| Zahaar | ? | ? | + | ? | + | + | + | + | + | – | ? | – | 6 |
| Brown | + | – | + | – | ? | + | + | – | ? | ? | – | + | 5 |
| Friedly | + | + | + | + | + | + | + | + | ? | + | + | + | 11* |
| Song | ? | ? | ? | ? | ? | + | + | – | ? | + | + | + | 5 |
| Milburn | ? | ? | + | – | + | – | + | – | ? | – | – | + | 4 |
| Hammerich | + | + | – | – | + | – | + | ? | ? | – | + | + | 6† |
| Sencan | + | ? | + | – | + | + | ? | + | + | + | ? | + | 8‡ |
| Wei | + | + | + | – | – | + | – | + | ? | + | + | + | 8* |
| Percutaneous epidural adhesiolysis | |||||||||||||
| Karm | + | ? | + | – | + | – | + | + | ? | – | – | + | 6‡ |
| Surgery versus physical therapy | |||||||||||||
| Zucherman | ? | + | – | – | + | + | + | + | ? | + | + | >6¶ | |
| Weinstein | + | + | – | – | + | + | + | + | ? | ? | – | + | >6 *** †† |
| Amundsen | + | ? | – | – | – | + | + | + | – | ? | – | ? | 4 |
| Malmivaara | + | + | – | – | + | + | + | + | + | ? | ? | + | 8* |
| Weinstein | + | + | – | – | + | – | + | + | ? | ? | – | + | 6†† |
| Delitto | + | + | – | – | + | ? | + | – | + | – | + | + | 7†† |
A: Was the method of randomisation adequate? B: Was the treatment allocation concealed? C: Was the patient blinded to the intervention? D: Was the care provider blinded to the intervention? E: Was the outcome assessor blinded to the intervention? F: Was the drop-out rate described and acceptable? G: Were all randomised participants analysed in the group to which they were allocated? H: Are reports of the study free of suggestion of selective outcome reporting? I: Were the groups similar at baseline regarding the most important prognostic indicators? J: Were cointerventions avoided or similar? K: Was the compliance acceptable in all groups? L: Was the timing of the outcome assessment similar in all groups? +: Yes, –: No, ?: Unclear.
*Low risk of bias if six or more items met, including valid randomisation and treatment allocation techniques and no severe flaws.
†<30 participants per treatment arm.
‡Treatment allocation unclear.
§Premature end of study.
¶2-year follow-up drop-out rate 30%, 1 year<20%; intention to treat inconsistent at 2-year follow-up.
**Drop-out rate<20% at 1 year, >20% at 4 years.
††Severe flaw due to high cross-over rates.